Sterling and TPI strike codeine agreement
Sterling Pharma Solutions’ site in Dudley, UK.
Agreement is the first step in TPI Enterprises’ plan to expand its presence in the UK market.
UK-based CDMO Sterling Pharma Solutions has established a toll processing agreement with TPI Enterprises to manufacture codeine phosphate (CPO) for sale in the UK market.
As part of the agreement, TPI Enterprises, one of three licensed poppy processors in Australia, will produce the narcotic raw material (NRM) at its site in Victoria, while Sterling Pharma Solutions will manufacture the CPO at its Dudley site near Newcastle, UK.
The UK market for CPO is one of the largest in the world, valued at around £20 million per annum. This agreement is the first step in TPI Enterprises’ plan to expand its presence in the UK market.
Kevin Cook, CEO at Sterling Pharma Solutions commented: “We are delighted to be the partner of choice to support TPI Enterprises during this exciting period of growth.
“At Sterling, we have developed the infrastructure and capabilities to handle, manufacture and store controlled substances meaning we are well positioned to support this project.”
The agreement provides TPI Enterprises with the means to leverage its unique low cost production advantage to expand its market share in a country that has traditionally high product demand, but very limited supply options.
Jarrod Ritchie, CEO at TPI Enterprises added: “The agreement will allow us to participate in the UK market and access a new, significant, and from a regulatory basis, previously inaccessible customer base.
“A combination of Sterling’s API production capability with our low cost raw material supply will greatly enhance customer options in the UK.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.